Q2 2022 Allergy Therapeutics PLC Earnings Call Transcript

Mar 10, 2022 / 10:30AM GMT
Operator

Good day, ladies and gentlemen, and welcome to the Allergy Therapeutics interim results. (Operator Instructions) I would like to remind all participants that this call is being recorded.

And now let me hand it over to the CEO of Allergy Therapeutics, Manuel Llobet, to open the presentation. Please go ahead.

Manuel Llobet - Allergy Therapeutics plc - CEO & Executive Director

Thank you very much, and good morning, everyone, and many thanks for joining us today for Allergy Therapeutics Interim Results for the 6 months ended December 2021.

Joining me today are 2 people that you know well, Nick Wykeman, Allergy's Chief Financial Officer; and Alan Bullimore, our Head of Business Innovation.

As you can see here in this slide, maintaining focus for a pivotal year ahead, this is really a pivotal year. It has taken us a lot of effort, investment, energy and passion to reach this year where 2 pivotal studies that can be transformational for the company are taking place. We will give you more details of these studies during the presentation.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot